Mercedes-Benz Plans to Sell Stake in Daimler Truck Holding
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 14 2026
0mins
Source: Benzinga
- Stake Sale Plan: Mercedes-Benz Group AG plans to sell its 35% stake in Daimler Truck Holding AG, valued at approximately €12 billion ($14.2 billion), to raise funds and return proceeds to shareholders, indicating a proactive liquidity strategy amidst market pressures.
- Market Challenges Ahead: Despite the cash infusion, Mercedes-Benz anticipates a tough year ahead, particularly in the Chinese market, where trade tensions and fierce competition are likely to keep margins flat, highlighting the complexities of the current industry landscape.
- Potential Unit Sale: Baker Hughes Co. is considering selling its Waygate Technologies unit, which specializes in industrial testing and inspection equipment, with a potential sale value of around $1.5 billion attracting interest from private equity firms, demonstrating the company's strategic intent to optimize its asset portfolio.
- ByteDance Transaction Progress: ByteDance is in advanced talks to sell Shanghai Moonton Technology to Saudi Arabia's Savvy Games Group for $6 billion to $7 billion, with the deal expected to close as soon as this quarter, reflecting ByteDance's strategic adjustments in the global market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HUM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HUM
Wall Street analysts forecast HUM stock price to fall
19 Analyst Rating
6 Buy
12 Hold
1 Sell
Moderate Buy
Current: 303.680
Low
231.00
Averages
290.39
High
344.00
Current: 303.680
Low
231.00
Averages
290.39
High
344.00
About HUM
Humana Inc. provides Humana insurance services and CenterWell health care services. The Company's segments include Insurance and CenterWell. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as its contract with CMS to administer the Limited Income Newly Eligible Transition (LI-NET) prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits. This segment also includes products consisting of employer group commercial fully-insured medical and specialty health insurance benefits marketed to individuals and employer groups. The CenterWell segment includes its pharmacy, primary care, and home solutions operations. The segment also includes its strategic partnerships with WCAS to develop and operate senior-focused, payor-agnostic, primary care centers, as well as its minority ownership interest in hospice operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Latest Wall Street Rating Updates
- Goldman Sachs Reiterates Buy on Broadcom: Goldman raised Broadcom's price target from $480 to $500, anticipating strong CapEx spending patterns from key customers, indicating that the upcoming earnings report may exceed market expectations.
- Oppenheimer Upgrades Rubrik: Oppenheimer upgraded Rubrik from Perform to Outperform with a price target of $85, based on strong checks from value-added resellers, highlighting the product's competitive strength in the market.
- UBS Upgrades Packaging Corp: UBS upgraded Packaging Corp from Neutral to Buy, expecting the $50/ton price hike to stick, which, combined with high utilization and prior capacity cuts, could add approximately $290 million in annualized EBITDA.
- Deutsche Bank Upgrades Humana: Deutsche Bank believes there is still time to buy shares of Humana, upgrading its rating to Buy, as it anticipates a new rally in managed care organizations that is just beginning.
See More
Market Dynamics and Earnings Preview Ahead
- Market Outlook: U.S. stock futures rise ahead of Nvidia's earnings report, breaking a three-day losing streak for the S&P 500, as President Trump hints at a quick end to the Iran war, leading to slight declines in oil prices and interest rates, which boosts market sentiment.
- Nvidia Earnings Anticipation: Nvidia is set to release its earnings tonight, with market expectations for a beat to drive a post-earnings rally; however, skepticism remains regarding its ability to maintain market share amidst competition from Amazon and Google’s in-house chips.
- Target's Performance Rebound: Under new CEO leadership, Target reported a quarterly earnings beat with same-store sales up 5.6%, significantly surpassing the 2.4% consensus, and raised its full-year net sales growth forecast to 4%, indicating strong growth in fashion and health products.
- UnitedHealth Stock Recovery: UnitedHealth has shown strong performance since CEO Steve Hemsley's return, with Mizuho raising its price target from $410 to $440, reflecting a 20% stock price increase over the past month, indicating market confidence in its growth trajectory.
See More
Analysts Upgrade Ratings for Robinhood and Humana Amid Market Dynamics
- Robinhood Upgrade: Analyst The Techie upgraded Robinhood from Hold to Buy, arguing that crypto headwinds are fully priced in while the strong performance in equities, options, and Gold subscriptions remains underappreciated, with the stock currently trading at $77 compared to an all-time high of $153.86 in October 2025, indicating a favorable risk-reward scenario.
- Humana Rebound Opportunity: Edmund Ingham upgraded Humana to Buy, noting that after a more than 65% decline in share price, improved CMS rate decisions and activist investor involvement are likely to support a turnaround, predicting the stock could exceed $450 before 2028, highlighting significant recovery potential.
- Apple Downgrade: Bay Area Ideas downgraded Apple from Buy to Hold, despite a strong Q2 revenue growth of 16.6%, citing stretched valuations and looming risks from price cuts in China and memory cost pressures, suggesting that the risk-reward profile has returned to a neutral state.
- Micron Downgrade: Victor Dergunov downgraded Micron to Sell, warning that its valuation nearing $1 trillion reflects excessive speculation, and expects margins to compress as the memory supply shortage normalizes, with a high probability of a price correction to around $600-500 before it becomes a buying opportunity again, indicating significant long-term valuation concerns.
See More
Earnings Season Volatility Hits US Stocks
- Strong Earnings Season: As the earnings season progresses, the S&P 500 reached an intraday record high of 7,501.24 on Thursday, reflecting strong investor confidence in corporate earnings, although it pulled back on Friday due to declines in tech stocks.
- Cisco's Stock Surge: Cisco shares soared 22% in one week following better-than-expected fiscal Q3 results, with a relative strength index (RSI) of 90 indicating the stock is in overbought territory, suggesting a potential short-term pullback risk.
- Zoetis Decline: Zoetis topped the oversold list with a 10% drop in the past week and an RSI of 14.4, as its Q1 earnings fell short of expectations and it lowered full-year EPS and revenue guidance, indicating pet owners are cutting back on vet visits due to price pressures.
- Market Sentiment Fluctuations: Despite strong performances from stocks like Cisco, the overall market experienced volatility due to disappointment over the U.S.-China summit outcomes, prompting investors to watch for potential rebounds in overbought and oversold stocks.
See More
Glenview Capital Management's Latest Investment Moves in Q1
- New Investments: In Q1 2023, Glenview Capital Management added Humana (HUM), Cisco (CSCO), Baker Hughes (BKR), Akamai (AKAM), and Intel (INTC), indicating a continued focus on healthcare and technology sectors, which may enhance portfolio diversification and risk mitigation.
- Exits from Holdings: The fund exited its positions in Expedia (EXPE), Knight-Swift (KNX), Accenture (ACN), IQVIA (IQV), and Qnity Electronics (Q), suggesting a cautious outlook on these companies, which could impact their stock performance negatively.
- Increased Stakes: Glenview increased its stake in Meta (META) by 111,090 shares valued at $62.5 million and in Cigna (CI) by 219,474 shares valued at $56.2 million, demonstrating strong confidence in these companies, which may drive their stock prices higher.
- Reduction in Holdings: The fund decreased its stake in Teva (TEVA) by 10 million shares, ZoomInfo (GTM) by 4.1 million shares, and Tenet (THC) by 458,899 shares, reflecting concerns about future growth potential, which may lead to a reassessment of these stocks in the market.
See More
U.S. Health Insurers Report Strong Q1 Results
- Strong Q1 Performance: Major U.S. health insurers, including UnitedHealth Group and Cigna, reported first-quarter results exceeding analysts' expectations, indicating improved cost management capabilities despite industry pressures that have seen the S&P managed care index drop over 12% since July 2023.
- Stabilizing Medical Costs: Analysts noted that while medical costs have continued to rise in government-sponsored health plans, recent performances suggest that cost trends may be stabilizing, with potential for further positive earnings estimate revisions reflecting improving fundamentals in the industry.
- Upcoming Quarter Challenges: Analysts caution that the second quarter typically serves as a test for health insurers, with historical data indicating that claims may surprise in May, prompting investors to closely monitor the upcoming months for financial performance.
- Positive Market Reaction: Despite seasonal factors impacting costs, analysts maintain an optimistic view on the industry's core strength, suggesting that the improvement in medical costs may be sustainable rather than a temporary occurrence, indicating a gradual enhancement of the industry's fundamentals.
See More
Latest Wall Street Rating Updates
- Goldman Sachs Reiterates Buy on Broadcom: Goldman raised Broadcom's price target from $480 to $500, anticipating strong CapEx spending patterns from key customers, indicating that the upcoming earnings report may exceed market expectations.
- Oppenheimer Upgrades Rubrik: Oppenheimer upgraded Rubrik from Perform to Outperform with a price target of $85, based on strong checks from value-added resellers, highlighting the product's competitive strength in the market.
- UBS Upgrades Packaging Corp: UBS upgraded Packaging Corp from Neutral to Buy, expecting the $50/ton price hike to stick, which, combined with high utilization and prior capacity cuts, could add approximately $290 million in annualized EBITDA.
- Deutsche Bank Upgrades Humana: Deutsche Bank believes there is still time to buy shares of Humana, upgrading its rating to Buy, as it anticipates a new rally in managed care organizations that is just beginning.
See More
Market Dynamics and Earnings Preview Ahead
- Market Outlook: U.S. stock futures rise ahead of Nvidia's earnings report, breaking a three-day losing streak for the S&P 500, as President Trump hints at a quick end to the Iran war, leading to slight declines in oil prices and interest rates, which boosts market sentiment.
- Nvidia Earnings Anticipation: Nvidia is set to release its earnings tonight, with market expectations for a beat to drive a post-earnings rally; however, skepticism remains regarding its ability to maintain market share amidst competition from Amazon and Google’s in-house chips.
- Target's Performance Rebound: Under new CEO leadership, Target reported a quarterly earnings beat with same-store sales up 5.6%, significantly surpassing the 2.4% consensus, and raised its full-year net sales growth forecast to 4%, indicating strong growth in fashion and health products.
- UnitedHealth Stock Recovery: UnitedHealth has shown strong performance since CEO Steve Hemsley's return, with Mizuho raising its price target from $410 to $440, reflecting a 20% stock price increase over the past month, indicating market confidence in its growth trajectory.
See More
Analysts Upgrade Ratings for Robinhood and Humana Amid Market Dynamics
- Robinhood Upgrade: Analyst The Techie upgraded Robinhood from Hold to Buy, arguing that crypto headwinds are fully priced in while the strong performance in equities, options, and Gold subscriptions remains underappreciated, with the stock currently trading at $77 compared to an all-time high of $153.86 in October 2025, indicating a favorable risk-reward scenario.
- Humana Rebound Opportunity: Edmund Ingham upgraded Humana to Buy, noting that after a more than 65% decline in share price, improved CMS rate decisions and activist investor involvement are likely to support a turnaround, predicting the stock could exceed $450 before 2028, highlighting significant recovery potential.
- Apple Downgrade: Bay Area Ideas downgraded Apple from Buy to Hold, despite a strong Q2 revenue growth of 16.6%, citing stretched valuations and looming risks from price cuts in China and memory cost pressures, suggesting that the risk-reward profile has returned to a neutral state.
- Micron Downgrade: Victor Dergunov downgraded Micron to Sell, warning that its valuation nearing $1 trillion reflects excessive speculation, and expects margins to compress as the memory supply shortage normalizes, with a high probability of a price correction to around $600-500 before it becomes a buying opportunity again, indicating significant long-term valuation concerns.
See More
Earnings Season Volatility Hits US Stocks
- Strong Earnings Season: As the earnings season progresses, the S&P 500 reached an intraday record high of 7,501.24 on Thursday, reflecting strong investor confidence in corporate earnings, although it pulled back on Friday due to declines in tech stocks.
- Cisco's Stock Surge: Cisco shares soared 22% in one week following better-than-expected fiscal Q3 results, with a relative strength index (RSI) of 90 indicating the stock is in overbought territory, suggesting a potential short-term pullback risk.
- Zoetis Decline: Zoetis topped the oversold list with a 10% drop in the past week and an RSI of 14.4, as its Q1 earnings fell short of expectations and it lowered full-year EPS and revenue guidance, indicating pet owners are cutting back on vet visits due to price pressures.
- Market Sentiment Fluctuations: Despite strong performances from stocks like Cisco, the overall market experienced volatility due to disappointment over the U.S.-China summit outcomes, prompting investors to watch for potential rebounds in overbought and oversold stocks.
See More
Glenview Capital Management's Latest Investment Moves in Q1
- New Investments: In Q1 2023, Glenview Capital Management added Humana (HUM), Cisco (CSCO), Baker Hughes (BKR), Akamai (AKAM), and Intel (INTC), indicating a continued focus on healthcare and technology sectors, which may enhance portfolio diversification and risk mitigation.
- Exits from Holdings: The fund exited its positions in Expedia (EXPE), Knight-Swift (KNX), Accenture (ACN), IQVIA (IQV), and Qnity Electronics (Q), suggesting a cautious outlook on these companies, which could impact their stock performance negatively.
- Increased Stakes: Glenview increased its stake in Meta (META) by 111,090 shares valued at $62.5 million and in Cigna (CI) by 219,474 shares valued at $56.2 million, demonstrating strong confidence in these companies, which may drive their stock prices higher.
- Reduction in Holdings: The fund decreased its stake in Teva (TEVA) by 10 million shares, ZoomInfo (GTM) by 4.1 million shares, and Tenet (THC) by 458,899 shares, reflecting concerns about future growth potential, which may lead to a reassessment of these stocks in the market.
See More
U.S. Health Insurers Report Strong Q1 Results
- Strong Q1 Performance: Major U.S. health insurers, including UnitedHealth Group and Cigna, reported first-quarter results exceeding analysts' expectations, indicating improved cost management capabilities despite industry pressures that have seen the S&P managed care index drop over 12% since July 2023.
- Stabilizing Medical Costs: Analysts noted that while medical costs have continued to rise in government-sponsored health plans, recent performances suggest that cost trends may be stabilizing, with potential for further positive earnings estimate revisions reflecting improving fundamentals in the industry.
- Upcoming Quarter Challenges: Analysts caution that the second quarter typically serves as a test for health insurers, with historical data indicating that claims may surprise in May, prompting investors to closely monitor the upcoming months for financial performance.
- Positive Market Reaction: Despite seasonal factors impacting costs, analysts maintain an optimistic view on the industry's core strength, suggesting that the improvement in medical costs may be sustainable rather than a temporary occurrence, indicating a gradual enhancement of the industry's fundamentals.
See More
